Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer answered questions about. When a caller inquired about the stock during the episode, Cramer said:

I like Eli Lilly very much. Look, I always, I never mind [when] anybody takes a profit, it’s always great to take a profit, but we’re holding on for the Charitable Trust. We think that Eli Lilly is one of our favorite stocks. We’re not budging. We’d buy more if it really got hit.

A laptop and a computer monitor display a detailed stock market technical analysis chart. Photo by Jakub Zerdzicki on Pexels

Eli Lilly and Company (NYSE:LLY) develops and markets medicines for diabetes, obesity, oncology, immunology, neuroscience, and other chronic conditions. Cramer discussed the company’s GLP-1s during the February 4 episode, as he commented:

We have the chief maker of the GLP-1s, Eli Lilly, soaring more than 10% as it rolls out trial after trial to see what these drugs can do beyond weight loss and diabetes, things like alcohol and tobacco addiction. They can make the ATF obsolete. Lilly’s got a joint venture with NVIDIA where they’re going… after hard-to-treat diseases. Hey, come on. With that kind of firepower, they’ll develop a new line of forever, people. Lilly’s gain is also arch rival Novo Nordisk’s pain. It’s not enough that President Trump wants to annex Greenland. Eli Lilly’s constantly taking share from Danish Novo Nordisk.

We recently mentioned the stock while discussing the best stocks for 20 years. You can read it here.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT:  33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.